Supernus Pharmaceuticals, Inc. (0LB2.L)
USD 32.03
(1.88%)
USD 32.03
(1.88%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.4 Billion USD | -17.24% |
| 2022 | 1.7 Billion USD | 0.79% |
| 2021 | 1.68 Billion USD | 12.3% |
| 2020 | 1.5 Billion USD | 29.63% |
| 2019 | 1.16 Billion USD | 18.66% |
| 2018 | 977.81 Million USD | 130.36% |
| 2017 | 424.46 Million USD | 37.11% |
| 2016 | 309.56 Million USD | 64.03% |
| 2015 | 188.73 Million USD | 37.25% |
| 2014 | 137.5 Million USD | 23.89% |
| 2013 | 110.99 Million USD | 18.09% |
| 2012 | 93.98 Million USD | 74.93% |
| 2011 | 53.73 Million USD | 14.3% |
| 2010 | 47 Million USD | -41.16% |
| 2009 | 79.89 Million USD | 3.59% |
| 2008 | 77.13 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1.31 Billion USD | 0.9% |
| 2024 Q3 | 1.34 Billion USD | 2.04% |
| 2024 Q1 | 1.3 Billion USD | -7.44% |
| 2023 Q2 | 1.29 Billion USD | -27.83% |
| 2023 Q1 | 1.79 Billion USD | 5.25% |
| 2023 Q4 | 1.4 Billion USD | 9.63% |
| 2023 FY | 1.4 Billion USD | -17.24% |
| 2023 Q3 | 1.28 Billion USD | -0.61% |
| 2022 Q4 | 1.7 Billion USD | 0.55% |
| 2022 FY | 1.7 Billion USD | 0.79% |
| 2022 Q1 | 1.63 Billion USD | -2.94% |
| 2022 Q2 | 1.69 Billion USD | 3.38% |
| 2022 Q3 | 1.69 Billion USD | -0.11% |
| 2021 Q2 | 1.57 Billion USD | 4.35% |
| 2021 Q4 | 1.68 Billion USD | 8.62% |
| 2021 Q1 | 1.5 Billion USD | 0.22% |
| 2021 FY | 1.68 Billion USD | 12.3% |
| 2021 Q3 | 1.55 Billion USD | -1.15% |
| 2020 Q3 | 1.51 Billion USD | 1.27% |
| 2020 Q1 | 1.18 Billion USD | 2.55% |
| 2020 Q2 | 1.49 Billion USD | 25.31% |
| 2020 FY | 1.5 Billion USD | 29.63% |
| 2020 Q4 | 1.5 Billion USD | -0.39% |
| 2019 Q4 | 1.16 Billion USD | 4.82% |
| 2019 FY | 1.16 Billion USD | 18.66% |
| 2019 Q1 | 1.02 Billion USD | 4.87% |
| 2019 Q2 | 1.06 Billion USD | 3.73% |
| 2019 Q3 | 1.1 Billion USD | 4.06% |
| 2018 Q1 | 825.16 Million USD | 94.4% |
| 2018 Q4 | 977.81 Million USD | 5.99% |
| 2018 FY | 977.81 Million USD | 130.36% |
| 2018 Q3 | 922.51 Million USD | 8.17% |
| 2018 Q2 | 852.79 Million USD | 3.35% |
| 2017 Q3 | 385.47 Million USD | 11.29% |
| 2017 FY | 424.46 Million USD | 37.11% |
| 2017 Q1 | 322.25 Million USD | 4.1% |
| 2017 Q2 | 346.37 Million USD | 7.48% |
| 2017 Q4 | 424.46 Million USD | 10.11% |
| 2016 FY | 309.56 Million USD | 64.03% |
| 2016 Q4 | 309.56 Million USD | 8.58% |
| 2016 Q3 | 285.11 Million USD | 30.41% |
| 2016 Q2 | 218.63 Million USD | 12.42% |
| 2016 Q1 | 194.47 Million USD | 3.04% |
| 2015 Q4 | 188.73 Million USD | 13.17% |
| 2015 FY | 188.73 Million USD | 37.25% |
| 2015 Q1 | 139.63 Million USD | 1.55% |
| 2015 Q2 | 154.16 Million USD | 10.41% |
| 2015 Q3 | 166.77 Million USD | 8.17% |
| 2014 Q1 | 97.52 Million USD | -12.14% |
| 2014 FY | 137.5 Million USD | 23.89% |
| 2014 Q4 | 137.5 Million USD | 8.85% |
| 2014 Q3 | 126.32 Million USD | 34.12% |
| 2014 Q2 | 94.19 Million USD | -3.41% |
| 2013 Q4 | 110.99 Million USD | -10.32% |
| 2013 FY | 110.99 Million USD | 18.09% |
| 2013 Q1 | 79.06 Million USD | -15.88% |
| 2013 Q2 | 131.97 Million USD | 66.93% |
| 2013 Q3 | 123.76 Million USD | -6.22% |
| 2012 Q1 | 43.2 Million USD | -19.59% |
| 2012 Q2 | 79.96 Million USD | 85.1% |
| 2012 FY | 93.98 Million USD | 74.93% |
| 2012 Q4 | 93.98 Million USD | 40.25% |
| 2012 Q3 | 67.01 Million USD | -16.2% |
| 2011 Q3 | 32.3 Million USD | 0.0% |
| 2011 Q4 | 53.73 Million USD | 66.34% |
| 2011 FY | 53.73 Million USD | 14.3% |
| 2010 FY | 47 Million USD | -41.16% |
| 2010 Q3 | 57.5 Million USD | 0.0% |
| 2010 Q4 | 47 Million USD | -18.25% |
| 2009 FY | 79.89 Million USD | 3.59% |
| 2009 Q4 | 79.89 Million USD | 0.0% |
| 2008 FY | 77.13 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | -69.412% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -751.325% |
| bluebird bio, Inc. | 619.16 Million USD | -127.562% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -1019.622% |
| Editas Medicine, Inc. | 499.15 Million USD | -182.274% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 94.719% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 58.011% |
| Myriad Genetics, Inc. | 1.19 Billion USD | -17.542% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 98.573% |
| Biogen Inc. | 26.84 Billion USD | 94.751% |
| Nektar Therapeutics | 398.03 Million USD | -253.985% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -50.352% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -81.13% |
| Imunon, Inc. | 21.91 Million USD | -6328.381% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 56.666% |
| Verastem, Inc. | 149.71 Million USD | -841.087% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 98.261% |
| Waters Corporation | 4.62 Billion USD | 69.548% |
| Perrigo Company plc | 10.8 Billion USD | 86.965% |
| Dynavax Technologies Corporation | 997.09 Million USD | -41.308% |
| Illumina, Inc. | 10.11 Billion USD | 86.065% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -4883.579% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -80.557% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -533.231% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -2044.888% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 79.406% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -752.273% |
| Evolus, Inc. | 188.99 Million USD | -645.498% |
| Adicet Bio, Inc. | 207.29 Million USD | -579.697% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -613.749% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 95.741% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -584.647% |
| FibroGen, Inc. | 423.52 Million USD | -232.675% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 86.909% |
| OPKO Health, Inc. | 2.01 Billion USD | 29.961% |
| Homology Medicines, Inc. | 47.05 Million USD | -2894.192% |
| Geron Corporation | 394.07 Million USD | -257.539% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 63.211% |
| Exelixis, Inc. | 2.94 Billion USD | 52.114% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -282.365% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -812.633% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -8.301% |
| Zoetis Inc. | 14.28 Billion USD | 90.137% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -139.526% |
| Abeona Therapeutics Inc. | 64 Million USD | -2101.458% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 93.801% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -2418.324% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 52.878% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 56.84% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -126.7% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 18.71% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -34.284% |
| Insmed Incorporated | 1.32 Billion USD | -5.951% |
| TG Therapeutics, Inc. | 329.58 Million USD | -327.498% |
| Incyte Corporation | 6.78 Billion USD | 79.225% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 23.212% |